Hb target achievement and associated predictors of roxadustat therapy across baseline anemia severities in maintenance hemodialysis: A single-center real-world retrospective cohort study
Retrospective cohort study examines hemoglobin targets with roxadustat in hemodialysis patients, highlighting predictors of success.
Key Points
To evaluate the effectiveness of roxadustat therapy in achieving hemoglobin targets across varying anemia severities in maintenance hemodialysis patients.
Retrospective cohort study involving 300 MHD patients who switched from ESAs to roxadustat monotherapy.
Patients grouped by baseline hemoglobin levels: severe (< 80 g/L), moderate (80-99 g/L), and mild (100-110 g/L).
Hb trajectories assessed with linear mixed-effects models; predictors analyzed using multivariable logistic regression.
At 12 weeks, sustained Hb achievement was 46.3% (severe), 64.2% (moderate), and 76.5% (mild), p=0.0012.
Hb variability decreased with lower coefficients of variation across the groups, p=0.008.
Predictors of lower target attainment included higher C-reactive protein (OR 0.42, p=0.012) and poor prior ESA response (OR 0.60, p=0.013).